Outcomes of Adolescent LBCL Patients Treated With Adult Type Chemotherapy: A Single Center Experience.

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-03-17 DOI:10.1016/j.clml.2025.03.009

Riad El Fakih, Taimoor Hussain, Oudai Sahwan, Ghaith Meir, Abdulwahab A Albabtain, Saud Alhayli, Abdullah Alamer, Mhd Anas Alsibai, Shamayel Mohammed, Ali Nasser, Muhammad Shahzad Rauf, Haifa Abdulrahman Alsuwaine, Irfan Maghfoor, Saad Akhtar, Alfadel Alshaibani, Walid Rasheed, Mahmoud Aljurf

{"title":"Outcomes of Adolescent LBCL Patients Treated With Adult Type Chemotherapy: A Single Center Experience.","authors":"Riad El Fakih, Taimoor Hussain, Oudai Sahwan, Ghaith Meir, Abdulwahab A Albabtain, Saud Alhayli, Abdullah Alamer, Mhd Anas Alsibai, Shamayel Mohammed, Ali Nasser, Muhammad Shahzad Rauf, Haifa Abdulrahman Alsuwaine, Irfan Maghfoor, Saad Akhtar, Alfadel Alshaibani, Walid Rasheed, Mahmoud Aljurf","doi":"10.1016/j.clml.2025.03.009","DOIUrl":null,"url":null,"abstract":"Background: Lymphoma is the most common cancer in adolescents. Outcome disparities based on the locus of care are increasingly recognized in this age group.Materials and methods: We report outcomes of LBCL patients between 14 and 21 who were treated at an adult center using adult type chemotherapy.Results: Sixty-four patients, median age 19 were analyzed. 82.8% were DLBCL, 17.2% were PMBCL; 21.9% stage I, 31.3% stage II, 7.8% stage III, and 39 % stage IV; 18.8% \"very good\", 62.5% \"good\" and 18.8% \"poor\" RIPI score. The median follow-up period was 68.8 months. The 5 years OS was 94.3%, and the 5 years EFS was 78.3%. High RIPI patients had a worse OS. High RIPI, B symptoms, ABC cell of origin and PMBCL had worse EFS.Conclusion: Pediatric protocol use should be restricted to patients at higher risk of events rather than to all these patients.","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clml.2025.03.009","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Lymphoma is the most common cancer in adolescents. Outcome disparities based on the locus of care are increasingly recognized in this age group.

Materials and methods: We report outcomes of LBCL patients between 14 and 21 who were treated at an adult center using adult type chemotherapy.

Results: Sixty-four patients, median age 19 were analyzed. 82.8% were DLBCL, 17.2% were PMBCL; 21.9% stage I, 31.3% stage II, 7.8% stage III, and 39 % stage IV; 18.8% "very good", 62.5% "good" and 18.8% "poor" RIPI score. The median follow-up period was 68.8 months. The 5 years OS was 94.3%, and the 5 years EFS was 78.3%. High RIPI patients had a worse OS. High RIPI, B symptoms, ABC cell of origin and PMBCL had worse EFS.

Conclusion: Pediatric protocol use should be restricted to patients at higher risk of events rather than to all these patients.

查看原文本刊更多论文

青少年LBCL患者接受成人型化疗的结果：单中心经验。

背景：淋巴瘤是青少年中最常见的癌症。在这个年龄组中，基于护理地点的结果差异越来越被认识到。材料和方法：我们报道了14 - 21岁的LBCL患者在成人中心接受成人型化疗的结果。结果：64例患者，中位年龄19岁。DLBCL占82.8%，PMBCL占17.2%；I期21.9%，II期31.3%，III期7.8%，IV期39%；“非常好”占18.8%，“好”占62.5%，“差”占18.8%。中位随访时间为68.8个月。5年OS为94.3%，5年EFS为78.3%。高RIPI患者的OS较差。高RIPI、B症状、ABC细胞源性和PMBCL均加重EFS。结论：儿科方案的使用应仅限于事件风险较高的患者，而不是所有这些患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.